Lilly Asia Ventures
Venture capitalHong Kong · Pre-Seed–Late Stage · 1 people tracked
Investment thesis
LAV positions itself as a long-term, biomedical-focused investor that partners with exceptional entrepreneurs seeking 'smart capital.' The firm emphasizes domain expertise, global resources, and long-term capital, betting on strong people, products, and quality science. Its investment scope covers biopharmaceuticals, human therapeutics, medical devices, and diagnostics, aiming to be a trusted partner in building great healthcare companies that develop products to treat diseases and improve human health.
Source: firm website, verified Aug 3, 2026.
Team · 1 people
from public directories
What they invest in
from 57 of 89 portfolio companiesBiotech ×52Healthtech ×36Medical Devices ×14AI & Machine Learning ×7Deep Tech ×7Digital Health ×7Hardware ×5Longevity ×2
HQs:United States×21China×19Germany×1
Who they back
founder profiles across 14 portfolio companiesFounding team size:solo founder×122 founders×13 founders×1
Investments · 89 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 12023 · 12022 · 12021 · 12020 · 42018 · 22017 · 113 dated
PartnerHongbo Lu· solo GP
Co-investorsLAVNew Enterprise Associates (NEA)Nextech InvestNSG Ventures
Legend Biotech is a biotechnology company.
BiotechSomerset, US
Yuan Xu, Ph.D.(Executive Officer, Director)Ying Huang, Ph.D.(Executive Officer)Fangliang Zhang, Ph.D.(Director)Ye Wang, M.S.(Director)
PartnerHongbo Lu· solo GP
Co-investorsLAV
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)Udayan Guha(Executive Officer)Steven P. Cobourn(Executive Officer)Sourav Kundu(Executive Officer)Kevin Shaw(Executive Officer)
PartnerHongbo Lu· solo GP
Co-investorsBay City CapitalCanaan PartnersLAVPfizer Venture InvestmentsQuan CapitalSofinnova Ventures+2 more
Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.
BiotechHealthtechLongevity
Geoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)
Co-investorsMPM BioImpactDCVC BioVersant VenturesDCVC (Data Collective)
San Diego, US
Board seatHongbo Lu· per SEC Form D · $5M raise · filed Aug 2020
Co-investorsAscenta CapitalLAVSilverArc PrivateTCG Crossover
BiotechHealthtechMedical DevicesWaltham, US
David F. Muller(Executive Officer, Director)Brian J. Roberts(Executive Officer)Rhonda J. Bracey(Executive Officer)
BoardJason Hong(Director)Jeff Dykan(Director)inAnthony Natale(Director)in
Board seatHongbo Lu· per SEC Form D
Co-investorsAPERTURE Venture PartnersLAVSCP Vitalife PartnersThird Point VenturesHealthQuest CapitalOrbiMed
BiotechSan Diego, US
JINGRONG JEAN CUI(Executive Officer, Director)Jingrong Jean Cui(Executive Officer, Director)YISHAN LI(Executive Officer, Director)Li Peter Yishan(Executive Officer, Director)
BoardGEORGE LEE(Director)CARL GORDON(Director)
Board seatHongbo Lu· per SEC Form D · $100M raise · filed Jan 2024
Perfuse Therapeutics is a biotechnology company developing a therapy to improve blood flow to the retina, targeting ocular diseases such as glaucoma and diabetic retinopathy.
BiotechMedical DevicesSan Francisco, US
BoardChristy Shaffer(Director)Chau Khuong(Director)inSevgi Gurkan(Executive Officer, Director, Promoter)in
Board seatHongbo Lu· per SEC Form D
Co-investorsAccess BiotechnologyCatalio Capital Management, LPHatteras Venture PartnersLAVOrbiMedHatteras
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)Hualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)Simon Xi(Co-founder and CEO)Jackie Walling(CMO)Debasish Roychowdhury(Director)
Board seatHongbo Lu· per SEC Form D · $38M raise · filed Mar 2021
Co-investorsDelos CapitalVivo CapitalAMR Action FundKorea Investment Partners
Alebund Pharmaceuticals develops innovative treatments for kidney diseases, with a pipeline covering chronic kidney conditions such as diabetic nephropathy, IgA nephropathy, FSGS, and ADPKD, as well as end-stage renal disease complications like hyperphosphatemia and anemia.
BiotechDigital HealthShanghai, CN
PartnerHongbo Lu· solo GP
Co-investorsLAVQuan Capital3E Bioventures CapitalSherpa Healthcare Partners
Allist (艾力斯医药) is a biopharmaceutical company that develops innovative drugs, with a product pipeline focused on treatments for non-small cell lung cancer (NSCLC) such as its EGFR-targeted therapy marketed as Furmonertinib (艾弗沙®).
BiotechHealthtech
PartnerHongbo Lu· solo GP
Ansun Biopharma develops therapeutics aimed at treating respiratory viral infections that lack existing treatment options.
BiotechSan Diego, US
RONALD MOSS(Executive Officer)MARK ATTEBURY(Executive Officer)MIKAEL HAVLUCIYAN(Executive Officer)
BoardALLEN CHAO(Director)MICHAEL CHANG(Director)NANCY CHANG(Director)
PartnerHongbo Lu· solo GP
Co-investorsLAV
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)Brent Rice(Chief Commercial Officer)
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
PartnerHongbo Lu· solo GP
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHongShan Capital GroupLAVOrbiMed+2 more
Burning Rock Dx is a diagnostics company that applies next-generation sequencing (NGS) technology to precision oncology, offering NGS-based assays for tissue and blood samples along with an in-house database.
BiotechDigital HealthMedical Devices
PartnerHongbo Lu· solo GP
Co-investorsLAV
Xian-ping LU(Founder)in
PartnerHongbo Lu· solo GP
Co-investorsLAVLYZZ CapitalVertex Ventures China
Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women.
BiotechFemTechHealthtechConcord, US
Mike Young(Founder)T Scott Johnson(Founder)inPaul Antinori(Executive Officer)Allison August(Executive Officer)Michael Young(Executive Officer)Thomas Scott Johnson(Executive Officer, Director)
Co-investorsAtlas VentureGV (Google Ventures)Broadview VenturesF-Prime CapitalNew Enterprise Associates (NEA)
Connect Biopharm develops next-generation therapeutics for inflammatory diseases.
Biotech
PartnerHongbo Lu· solo GP
Co-investorsLAVQiming Venture Partners
CorrectSequence Therapeutics (正序生物) develops precision therapies based on its proprietary base editing platform, targeting genetic diseases such as thalassemia and sickle cell disease.
BiotechDeep TechHealthtechShanghai, CN
牟晓盾(CEO)
PartnerHongbo Lu· solo GP
Co-investorsLAV
Landos Technology (朗来科技) is a clinical-stage drug discovery and development company with a pipeline of novel small-molecule therapies for indications including hypertension, chronic heart failure, IgA nephropathy, FSGS, chronic cough, idiopathic pulmonary fibrosis, and autoimmune diseases such as rheumatoid arthritis and psoriasis.
BiotechHealthtechWuhan, CN
Co-investorsOrbiMedVivo Capital
Crown Bioscience is a contract research organization (CRO) providing preclinical and translational research services in oncology and immuno-oncology drug discovery, including a large library of cancer models such as PDX, cell line derived xenografts, syngeneic, and in vitro models.
BiotechHealthtech
PartnerHongbo Lu· solo GP
Co-investorsAcorn Pacific VenturesGRC SinogreenLAVQiming Venture Partners
Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
BiotechDigital Health
PartnerHongbo Lu· solo GP
Co-investorsLAVMPM BioImpactSchooner CapitalTaiho Ventures, LLC
EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform.
BiotechDeep TechHealthtech
PartnerHongbo Lu· solo GP
Co-investorsLAVWI Harper Group
Fortis Therapeutics develops precision cancer therapies that target CD46 proteins on tumor cells while sparing healthy tissue.
BiotechHealthtech
Co-investorsAvalon BioVenturesOUP (Osage University Partners)Vivo CapitalOsage University Partners
Skyline Therapeutics develops gene therapies using an adeno-associated virus (AAV) platform that combines capsid discovery, vector engineering, process development, and GMP manufacturing.
BiotechHealthtech
PartnerHongbo Lu· solo GP
Co-investorsF-Prime CapitalLAV
Geneseeq develops next-generation sequencing (NGS) based genetic tests and in-vitro diagnostic products for cancer patients, using gene profiling to guide targeted drug selection, indicate drug resistance mechanisms, and monitor post-surgical recurrence.
AI & Machine LearningBiotechDigital HealthNanjing, CN
PartnerHongbo Lu· solo GP
Co-investorsLAV
Gracell develops CAR-T cell therapies aimed at delivering fast, deep, and durable responses for patients with cancer and autoimmune disease.
BiotechHealthtech
PartnerHongbo Lu· solo GP
Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.
BiotechDeep TechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
PartnerHongbo Lu· solo GP
Co-investorsBay City CapitalGV (Google Ventures)LAV
Beijing Huamai Taike Medical Instrument develops, manufactures, and sells medical devices for treating vascular diseases, covering the aortic, peripheral, coronary, and neurointervention/access areas.
HardwareHealthtechMedical DevicesBeijing, CN
PartnerHongbo Lu· solo GP
Co-investorsLAV
Inhibrx develops protein therapeutics, using target biology and protein engineering to create therapeutic candidates in clinical trials for conditions including sarcoma and head and neck cancer.
BiotechLa Jolla, US
Mark Lappe(Executive Officer, Director)Brendan Eckelman(Director)Doug Forsyth(Director)Jon Faiz Kayyem(Director)Margery Fischbein(Director)
BoardJudith Li(Director)
PartnerHongbo Lu· solo GP
Co-investorsLAVRA CapitalOxford Finance LLC
PartnerHongbo Lu· solo GP
Co-investorsF-Prime CapitalLAVLegend Capital
Insilico Medicine applies computational and AI-based modeling to drug design and problems such as protein folding for pharmaceutical research and development.
AI & Machine LearningBiotechHealthtechHong Kong
Alex Zavoronkov(Director)Alex Zhavoronkov(Founder & CEO)
BoardNisa Leung(Director)Lennart Lee(Director)James Mellon(Director)
PartnerHongbo Lu· solo GP
Co-investorsB Capital GroupB4 CapitalBOLD LongevityF-Prime CapitalGestio CapitalLAV+5 more
InventisBio (益方生物) is a biopharmaceutical company that develops small-molecule drugs, including candidates targeting KRAS G12C for lung and pancreatic cancer and treatments for moderate-to-severe plaque psoriasis.
BiotechHealthtechShanghai, CN
Xing Dai(Founder)in
PartnerHongbo Lu· solo GP
Co-investorsLAVOrbiMedQiming Venture Partners
Jacobio Pharmaceuticals is a biotech company that develops first-in-class oncology drugs using its allosteric drug discovery platform and iADC platform, targeting difficult-to-drug targets across validated tumor signaling pathways.
BiotechDeep TechHealthtech
PartnerHongbo Lu· solo GP
Co-investorsLAVQiming Venture Partners
Kechow Pharma is a clinical-stage drug discovery company developing original novel small-molecule therapies for oncology and free-radical-related diseases.
BiotechHealthtech
Co-investorsDecheng CapitalQiming Venture Partners
Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.
BiotechMedical Devices
Co-investorsForesite CapitalNextech InvestAlexandriaLongwood Fund
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)FRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)JAMES GILBERT(Director)
BoardALAN L. CRANE(Director)
PartnerHongbo Lu· solo GP
Co-investorsAlpha Wave GlobalARCH Venture PartnersFlagship PioneeringLAVBaillie GiffordPolaris Partners
Lynk Pharmaceuticals is a clinical-stage drug company developing small-molecule therapies for autoimmune and inflammatory diseases, targeting JAK-STAT and TYK2 signaling pathways and using targeted protein degradation to create oral alternatives to biologics.
AI & Machine LearningBiotechHealthtech
PartnerHongbo Lu· solo GP
Co-investorsDecheng CapitalLAV
PartnerHongbo Lu· solo GP
Co-investorsB Capital GroupB4 CapitalF-Prime CapitalLAVMarathon Venture Partners
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
PartnerHongbo Lu· solo GP
Co-investorsage1EcoR1 CapitalLAVNew Enterprise Associates (NEA)Vivo CapitalARCH Venture Partners+2 more
MicroTech Medical produces the Equil patch insulin pump, a tubeless wearable pump for people managing diabetes, and references the Aidex continuous glucose monitoring system (CGMS) for real-time glucose tracking.
Digital HealthHardwareMedical Devices
PartnerHongbo Lu· solo GP
Co-investorsLAVLYZZ CapitalQiming Venture Partners
PartnerHongbo Lu· solo GP
Co-investorsAcorn Pacific VenturesLAVLegend Capital
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.
BiotechHealthtechWilmington, CN
Yan Lou(Founder)Gary Yeung(Director)Ting Jia(Director)Hong (Kelsey) Chen(Chief Financial Officer)Zhenhai Gao(President, CEO, and Secretary)Roderick Wong(Director)
PartnerHongbo Lu· solo GP
Co-investorsEcoR1 CapitalLAVRA CapitalSamsara BioCapitalThe Innovation SpaceLogos
Nucleix develops liquid biopsy and molecular diagnostic tests for early cancer detection, including its Bladder EpiCheck test for bladder and upper tract urinary cancer and a blood test in development for early-stage lung cancer.
BiotechHealthtechMedical Devices
Co-investorsGefen CapitalOrbiMedRA CapitalBlackRockLYFE CapitalSands Capital Ventures
BiotechCampbell, US
Amr Salahieh(Executive Officer, Director)Casey Gordon(Director)Mariam Maghribi(Executive Officer)
PartnerHongbo Lu· solo GP
Co-investorsLAV
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.
AI & Machine LearningBiotechDigital HealthBoston, US
Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)Sylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)Toni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)
Co-investorsIllumina Ventures5AM VenturesOUP (Osage University Partners)Osage University Partners
PartnerHongbo Lu· solo GP
Co-investorsB Capital GroupB4 CapitalLAVLYFE CapitalNextech InvestRA Capital
Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.
BiotechDeep TechHardwareHealthtechCambridge, US
Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)
BoardYuh-Geng Tsay(Director)Victor Tong(Director)Thomas Grogan(Director)
PartnerHongbo Lu· solo GP
Co-investorsLAVLilly VenturesVivo Capital
Regor is a drug discovery company that uses a computational platform (rCARD) to identify and optimize preclinical small-molecule candidates in metabolism, oncology, and immunology, which it licenses to pharmaceutical companies for clinical development.
AI & Machine LearningBiotechDeep TechShanghai, CN
Xiayang Qiu(Founder)in
PartnerHongbo Lu· solo GP
Co-investorsLAVVertex Ventures
RemeGen is a biopharmaceutical company that develops and commercializes novel antibody and fusion protein therapeutics, including telitacicept (a BLyS/APRIL dual-target fusion protein) and disitamab vedotin, for conditions such as autoimmune diseases and cancers.
BiotechHealthtechYantai, CN
王威东(Co-founder)房健民(Co-founder)
PartnerHongbo Lu· solo GP
Co-investorsLAV
Rona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH.
BiotechLongevityShanghai, CN
Jinyu Huang(Chief Executive Officer, Founder)Stella Shi(Founder & Chief Executive Officer, Chair of the Board)Stella (Yibin) Shi(Founder)
PartnerHongbo Lu· solo GP
Co-investorsLAV
Ronovo Surgical develops the Carina surgical robotics platform, including a vision system and instruments, for use by surgeons and hospitals.
HealthtechMedical DevicesRoboticsShanghai, CN
John Ma(Founder)Ying Mao(Founder)
Co-investorsGranite AsiaINCE CapitalVivo CapitalJJDC
Singlera Genomics develops DNA methylation-based molecular diagnostics for cancer, covering early detection, diagnosis, and recurrence monitoring across multiple cancer types including colorectal, liver, gastric, esophageal, and pancreatic cancers.
BiotechHealthtechMedical DevicesShanghai, CN
PartnerHongbo Lu· solo GP
Singleron Biotechnologies develops single-cell and single-nucleus sequencing kits and solutions for transcriptome analysis of biological samples.
BiotechMedical DevicesCologne, DE
PartnerHongbo Lu· solo GP
Co-investorsARCH Venture PartnersLAVMSA Capital
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Executive Officer, Director, Promoter)
BoardFan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)
PartnerHongbo Lu· solo GP
Co-investors8VCARCH Venture PartnersFrazier Life SciencesJDRF T1D FundLAVLifeforce Capital+1 more
Sperogenix (曙方医药) is a biopharmaceutical company focused on developing and commercializing drugs for genetic rare diseases in China, covering areas such as neuromuscular disorders, neurodevelopmental disorders, inherited metabolic diseases, and blood disorders.
BiotechHealthtech
PartnerHongbo Lu· solo GP
Co-investorsLAV
Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.
BiotechHealthtechBrisbane, US
Stephen Brady(Director)Matthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)Thomas Woiwode(Director)Geoffrey Nichol(Director)Thomas W. Dubensky(Executive Officer, Director)
PartnerHongbo Lu· solo GP
Co-investorsF-Prime CapitalLAVNew Enterprise Associates (NEA)Quan CapitalRoche Venture Fund
Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program.
BiotechHealthtechFoster City, US
Mark Vignola, Ph.D.(Executive Officer)Bryan Yoon(Executive Officer)Senthil Sundaram(Director, Executive Officer)Weidong Zhong, Ph.D.(Executive Officer, Director)Jill Quigley(Director)David Fellows(Director)
PartnerHongbo Lu· solo GP
Co-investorsDecheng CapitalLAVVivo Capital
BiotechPhiladelphia, US
Anne Chew(Director and President)
BoardKevin Mahoney(Director)
PartnerHongbo Lu· solo GP
Co-investorsAndreessen HorowitzKleiner PerkinsLAVMilitia Hill VenturesGilead Sciences
PartnerHongbo Lu· solo GP
Co-investorsForesite CapitalLAVNextech InvestSv Tech Ventures, Inc.
PartnerHongbo Lu· solo GP
Co-investorsLAVPfizer Venture Investments
Innovative biopharma company focused on cancer and immune disease therapies (SHSE: 688192).
PartnerHongbo Lu· solo GP
Co-investorsHongShan Capital GroupLAV
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 4
IPOs and acquisitions across the tracked portfolioBlack Diamond Therapeutics, IncNASDAQ: BDTXLegend BiotechNASDAQ: LEGNNextCureNASDAQ: NXTCAvedroacq. by Glaukos
Portfolio news
latest coverage across their companiesInhibrx · ng.investing.com · Aug 21, 2026
Terns Pharmaceuticals · tradingkey.com · Aug 20, 2026
Arrivent · tickerreport.com · Aug 17, 2026
Khartis Therapeutics · allsci.com · Aug 14, 2026
Alebund · fiercebiotech.com · Aug 12, 2026
Tempest Therapeutics · tipranks.com · Jul 22, 2026
NextCure · investing.com · Jul 15, 2026
Fund performance · per public LP disclosures · 4
as of Sep 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| LAV Fund VI Opportunities, L.P.LPs: Los Angeles County Employees Retirement Association, California State Teachers' Retirement System, Robert Wood Johnson Foundation | 2021 | — | 3.2% | 1.10x | 0.14x |
| LAV Fund VI, L.P.LPs: Los Angeles County Employees Retirement Association, California State Teachers' Retirement System, Robert Wood Johnson Foundation | 2021 | — | 9.1% | 1.27x | 0.29x |
| LAV Biosciences Fund V, L.P.LPs: Los Angeles County Employees Retirement Association, California State Teachers' Retirement System | 2019 | — | 6.3% | 1.29x | 0.37x |
| LAV Biosciences Fund IV, L.P.LPs: Los Angeles County Employees Retirement Association, California State Teachers' Retirement System | 2017 | — | 14.5% | 1.85x | 1.11x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has Lilly Asia Ventures made?
- Lilly Asia Ventures has 73 tracked investments, 2 of which have exited via acquisition or IPO.
- What stage does Lilly Asia Ventures invest at?
- Lilly Asia Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Lilly Asia Ventures focus on?
- Lilly Asia Ventures focuses on Biotech, Digital Health, EdTech, Healthtech, Medical Devices.
- Where is Lilly Asia Ventures located?
- Lilly Asia Ventures is headquartered in Hong Kong, HK.
- Does Lilly Asia Ventures lead rounds?
- Lilly Asia Ventures typically participates in rounds rather than leading them.
- Who does Lilly Asia Ventures co-invest with?
- Lilly Asia Ventures most often shares deals with LAV, Qiming Venture Partners, OrbiMed, among 60 tracked co-investors.
Images
Co-investors · 7
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
Wildcat Venture Partners is a venture capital firm that backs technology entrepreneurs aiming to create new market categories.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
HBM Partners is a Swiss healthcare-focused investment firm managing USD 2.1 billion, investing in private and public companies across biopharma, medtech, diagnostics and healthcare. It advises HBM Healthcare Investments Ltd and other specialised funds.
Boehringer Ingelheim Venture Fund, established in 2010, invests in biotechnology companies developing therapeutics in immuno-oncology, regenerative medicine, and gene therapy, including platform technologies and novel vaccines. The fund targets early-stage companies addressing unmet medical needs through translational research and scientific innovation.
Firms observed investing alongside Lilly Asia Ventures, from public investor directories. Shared companies are the overlap with Lilly Asia Ventures's recorded portfolio.
Similar investors
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Norwest Venture Partners is an investment firm whose growth equity team backs private, profitable, fast-growing companies, providing capital and hands-on support through its 'invited guest' approach.
OneVentures is a later-stage venture capital firm that backs technology and healthcare companies, providing growth equity and credit alongside strategic and operational support.
Olive Tree Capital invests in technology and life sciences companies, backing entrepreneurs across healthcare, fintech, enterprise, AI/ML, and frontier technology sectors.
SBI Investment Korea is a Korean asset management firm within the SBI Group that operates venture capital and private equity funds, positioning itself as a 'New Industry Creator'.